$120 Million Investment to Produce COVID-19 Oral Treatments — Precision Vaccinations
New York-based Pfizer Inc. announced today that it would further strengthen its commitment to U.S. manufacturing with a $120 million investment at its Kalamazoo, Michigan, facility.
This new investment will enable U.S.-based production to support its U.S. FDA-approved COVID-19 oral treatment, Paxlovid™.
The investment will expand the production of active pharmaceutical ingredients (API) and registered starting materials (RSMs) used in the manufacture of nirmatrelvir, a novel main protease (Mpro) inhibitor originating in Pfizer’s laboratories.
“Pfizer Global Supply has made the impossible possible, making billions of vaccine doses and now millions of treatment courses to help battle the deadly COVID-19 pandemic,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer, in a press release issued on June 6, 2022.
“By increasing production at our Michigan facility, we are both helping patients around the world and expanding important manufacturing innovation to the U.S.”
“This investment builds upon our $5 billion of investments across our manufacturing and distribution portfolio since 2017 to support the ongoing growth of U.S. manufacturing leadership.”
To date, Pfizer has shipped 12 million courses of Paxlovid across 37 countries, including 5 million courses shipped to the U.S., and has manufactured almost 17 million treatment courses total.
RSMs are the raw materials chemically converted into API, the active ingredient in medicine.
With this new investment, Kalamazoo will be among the world’s largest producers of API, with the capacity to produce 1,200 metric tons annually.
Pfizer also plans to expand its Modular Aseptic Processing (MAP) sterile injectable pharmaceutical production facility in Kalamazoo with a phase two investment.
The expansion adds to the initial investment of $450 million in phase one to build a 400,000-square-foot production facility and further establishes Kalamazoo, located in south/central Michigan, as one of the world’s most technically advanced sterile injectable pharmaceutical production facilities.
Note: This announcement was manually curated for mobile readership.